Evidence map›Paper›PMID 42631246›Full record

ArticleGlobal heart2026

Impact of Adopting the Race/Ethnicity-Free 2021 CKD-EPI Equation on Cardiovascular Risk Stratification in a Multiethnic European Population: Results from the HELIUS Study.

Brechje J M V Huisman, Taryn G Vosters, Charles Agyemang, Bert-Jan H van den Born, Irene G M van Valkengoed, Liffert Vogt

Abstract readMulticenter Study
In one paragraph

Article in Global heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brechje J M V HuismanDepartment of Internal Medicine, Section Nephrology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0009-0000-0628-0072
Taryn G VostersDepartment of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health (APH) Research Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0009-0009-9712-3894
Charles AgyemangDepartment of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health (APH) Research Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-3882-7295
Bert-Jan H van den BornDepartment of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health (APH) Research Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-0943-4393
Irene G M van ValkengoedDepartment of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health (APH) Research Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-9306-7831
Liffert VogtDepartment of Internal Medicine, Section Nephrology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-4585-7505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: To assess the impact of the race-free 2021 CKD-EPI equation compared with the 2009 CKD-EPI equation (with/without race correction) on chronic kidney disease (CKD) detection and cardiovascular (CV) risk categorization in a multiethnic European population. Methods: This cross-sectional analysis included 21,617 participants of the Healthy Life in an Urban Setting (HELIUS) study in Amsterdam: Dutch, South-Asian Surinamese, African Surinamese, Ghanaian, Turkish, and Moroccan adults aged 18-70 years. Estimated glomerular filtration rate (eGFR) was calculated using the 2009 CKD-EPI equation (with/without race coefficient) and the race-free 2021 CKD-EPI equation. CKD was defined as eGFR <60 mL/min/1.73 m Results: Compared with the 2009 equation, the 2021 equation yielded lower eGFR values in African Surinamese and Ghanaian participants and marginally higher values in other groups. This led to a modest increase in CKD prevalence among those of African ancestry but did not affect overall CKD classification (Cohen's κ = 0.94-0.99). Sensitivity, specificity, and C-statistics for CKD detection in risk groups were similar across equations. Integration of CKD modestly increased CV risk estimates, but results were virtually identical across the 2009 and 2021 equations. Conclusion: In this multiethnic European cohort, the race-free 2021 CKD-EPI equation produced different kidney function estimates, but both CKD and CV risk classifications were nearly identical to the 2009 equation. These findings support their clinical interchangeability and endorse adoption of the race-free equation as an equitable and reliable standard for kidney function assessment and CV risk prediction. Lay Summary: In this large, multiethnic European cohort, adoption of the race-free 2021 CKD-EPI equation did not meaningfully alter chronic kidney disease (CKD) detection or cardiovascular (CV) risk stratification compared with the 2009 equation.The 2021 CKD-EPI equation lowered estimated glomerular filtration rate (eGFR) in individuals of African descent living in Europe but did not change CKD detection.Agreement between the 2009 and 2021 CKD-EPI equations for CKD classification was almost perfect, and CV risk categorization using SCORE2 and SCORE2 CKD Add-on tools was largely unaffected, indicating that adopting the race-free CKD-EPI equation is unlikely to alter CV risk management at the population level.

Indexed as

Cardiovascular DiseasesEthnicityGlomerular Filtration RateRacial GroupsRenal Insufficiency, ChronicAdolescentAdultAgedCross-Sectional StudiesEuropean PeopleFemaleHumansMaleMiddle AgedNetherlandsPrevalencecardiovascular predictionchronic kidney disease (CKD)CKD-EPI equationmultiethnic populationrace-free kidney function estimationSCORE2/SCORE2 Add-on

Identifiers

PMID42631246
PMCPMC13496232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.